Alpine Financial Statements From 2010 to 2024
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
Check Alpine Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alpine Immune's main balance sheet or income statement drivers, such as , as well as many indicators such as . Alpine financial statements analysis is a perfect complement when working with Alpine Immune Valuation or Volatility modules.
Alpine |
Alpine Immune Sciences Company Current Valuation Analysis
Alpine Immune's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alpine Immune Current Valuation | 4.16 B |
Most of Alpine Immune's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alpine Immune Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Alpine Immune Sciences has a Current Valuation of 4.16 B. This is 71.03% lower than that of the Biotechnology sector and 10.43% lower than that of the Health Care industry. The current valuation for all United States stocks is 74.97% higher than that of the company.
Alpine Immune Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alpine Immune's current stock value. Our valuation model uses many indicators to compare Alpine Immune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alpine Immune competition to find correlations between indicators driving Alpine Immune's intrinsic value. More Info.Alpine Immune Sciences is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alpine Immune's earnings, one of the primary drivers of an investment's value.About Alpine Immune Financial Statements
Alpine Immune investors utilize fundamental indicators, such as revenue or net income, to predict how Alpine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Alpine Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Transaction History View history of all your transactions and understand their impact on performance |